EGFR/HER2-IN-18 is a stable dual inhibitor targeting EGFR and HER2, with IC50 values of 0.09 µM and 0.08 µM, respectively. It exhibits broad-spectrum anticancer activity and can induce apoptosis and inhibit the cell cycle in MCF-7 cells. EGFR/HER2-IN-18 is applicable for breast cancer research.
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
